Table 1.
Prevalence of hypertension among US adults with traditional and new criteria for the diagnosis of hypertension in NHANES 2013-2014
| Characteristic | Prevalence with traditional criteria* (95% CI) |
Prevalence with new criteria† (95% CI) |
Absolute difference in prevalence (95% CI) |
Relative percent difference in prevalence (95% CI) |
|---|---|---|---|---|
| Overall | 34.2 (32.5, 35.8) | 44.0 (42.2, 45.7) | 9.8 (8.7, 11.1) | 28.6 (25.0, 33.1) |
| Age | ||||
| 20-39 | 8.7 (7.3, 10.0) | 17.1 (15.4, 18.9) | 8.4 (7.3, 9.8) | 97.1 (76.5, 122.7) |
| 40-59 | 34.7 (31.9, 37.5) | 47.6 (44.7, 50.7) | 12.9 (11.0, 15.0) | 37.3 (31.4, 45.5) |
| ≥60 | 72.4 (69.8, 75.5) | 79.7 (77.2, 82.1) | 7.2 (5.5, 9.0) | 10.0 (7.5, 12.8) |
| Gender | ||||
| Male | 35.0 (32.6, 37.5) | 46.7 (44.1, 49.4) | 11.7 (10.1, 13.4) | 33.2 (28.4, 39.6) |
| Female | 33.5 (31.1, 35.4) | 41.5 (39.3, 43.5) | 8.1 (6.9, 9.2) | 24.2 (20.3, 28.7) |
| Race/Ethnicity | ||||
| White, non-Hispanic | 36.8 (34.5, 39.2) | 46.2 (44.0, 48.7) | 9.4 (8.0, 10.9) | 25.5 (21.0, 30.5) |
| Black, non-Hispanic | 41.1 (38.0, 44.0) | 52.3 (49.4, 55.4) | 11.1 (9.4, 13.2) | 27.1 (21.9, 32.8) |
| Asian, non-Hispanic | 25.9 (22.0, 29.5) | 34.3 (30.3, 38.2) | 8.4 (6.5, 10.7) | 32.7 (24.3, 43.3) |
| Hispanic | 21.5 (19.6, 23.8) | 31.9 (29.4, 34.6) | 10.4 (8.7, 12.2) | 48.2 (38.7, 58.5) |
| Diabetes | ||||
| No | 28.7 (27.0, 30.5) | 38.8 (37.0, 40.9) | 10.1 (8.9, 11.5) | 35.2 (30.3, 41.2) |
| Yes | 75.6 (72.0, 79.1) | 82.2 (79.1, 85.0) | 6.5 (4.7, 8.8) | 8.7 (6.0, 12.0) |
| Prevalent CVD | ||||
| No | 29.9 (28.1, 31.6) | 40.2 (38.4, 42.1) | 10.4 (9.2, 11.7) | 34.6 (30.3, 40.3) |
| Yes | 82.0 (77.3, 86.5) | 85.4 (81.1, 89.2) | 3.4 (1.9, 5.4) | 4.2 (2.3, 6.8) |
| ASCVD Risk | ||||
| < 10% | 20.4 (18.6, 22.1) | 30.5 (28.6, 32.7) | 10.2 (8.9, 11.6) | 49.9 (42.0, 59.2) |
| ≥ 10% | 76.7 (74.1, 79.4) | 84.4 (82.2, 86.4) | 7.6 (5.6, 9.6) | 9.9 (7.1, 12.8) |
| BMI (kg/m2) | ||||
| < 25 | 21.6 (19.2, 24.1) | 29.0 (26.4, 31.6) | 7.3 (6.0, 8.8) | 34.0 (26.8, 43.1) |
| 25 - < 30 | 33.0 (30.4, 36.0) | 42.8 (40.0, 45.8) | 9.7 (8.0, 11.4) | 29.3 (23.3, 35.7) |
| ≥ 30 | 44.4 (41.7, 47.2) | 56.3 (53.7, 59.1) | 11.9 (10.4, 13.8) | 26.7 (22.7, 32.4) |
| eGFR < 60 mL/min/1.73m2 | ||||
| ≥ 60 | 30.0 (28.2, 31.7) | 40.2 (38.5, 42.2) | 10.3 (9.1, 11.6) | 34.4 (29.7, 39.8) |
| < 60 | 84.9 (80.8, 88.6) | 87.3 (83.5, 90.3) | 2.3 (0.8, 4.2) | 2.7 (1.0, 5.1) |
| Urine ACR (mg/g) | ||||
| < 30 | 30.9 (29.1, 32.6) | 40.7 (39.0, 42.6) | 9.8 (8.7, 11.1) | 31.6 (27.4, 37.2) |
| ≥ 30 | 59.2 (54.4, 63.4) | 68.8 (63.9, 72.8) | 9.5 (7.3, 12.0) | 16.2 (11.5, 21.0) |
Cell contents are proportions (%) (95% CI).
Abbreviations: CVD, cardiovascular disease; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACR, albumin to creatinine ratio.
All prevalence estimates account for the persistence of hypertension (supplement).
*
Defined as SBP ≥140 mmHg, DBP≥90 mm Hg, and/or current use of antihypertensive medication.
†
Defined as SBP≥130 mmHg, DBP≥80 mm Hg, and/or current use of antihypertensive medication.